CA19-9

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Retrieved on: 
Thursday, April 25, 2024
PFS, Efficacy, Safety, DCR, Risk, Nivolumab, Randomness, SOC, Drug resistance, Death, CM24, Tumor microenvironment, OS, PD-1, PDAC, ASCO, Cancer, Patient, Society, CA19-9, Interim, BMS, Neoplasm, Bristol Myers Squibb, Annual general meeting, Pharmacodynamics, Escape Room, Pharmaceutical industry

REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that interim results from its randomized, controlled, open label, multicenter Phase 2 study of CM24, a first in class immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC), have been selected as late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting which will take place on May 31 – June 4, 2024 in Chicago, Illinois.

Key Points: 
  • The primary endpoint of the study is overall survival (OS), with progression free survival (PFS) and objective response rate (ORR) as secondary endpoints.
  • The study was designed as Bayesian to evaluate the potential benefit of the experimental arm vs SoC and is not powered for hypothesis testing.
  • Approximately 60 patients have been enrolled in the randomized study in 18 centers in the U.S., Spain and Israel.
  • “We are honored to be selected by the ASCO committee with our late breaking abstract poster presentation and are looking forward to presenting our interim results from our randomized Phase 2 CM24 study at the ASCO 2024 annual meeting.” stated Gil Efron, Chief Executive Officer of Purple Biotech.

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Retrieved on: 
Monday, April 22, 2024
Cancer, Risk, Pancreatic cancer, ELISA, Survival, EUS, Heredity, PDAC, Patient, MRI, Magnetic resonance imaging, CA19-9, Biomarker, Medical imaging

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Key Points: 
  • The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
  • Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
  • Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer.
  • People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early.

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Retrieved on: 
Monday, April 22, 2024
Cancer, Risk, Pancreatic cancer, ELISA, Survival, EUS, Heredity, PDAC, Patient, MRI, Magnetic resonance imaging, CA19-9, Biomarker, Medical imaging

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Key Points: 
  • The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
  • Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
  • Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer.
  • People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early.

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Retrieved on: 
Wednesday, January 17, 2024
Tumor microenvironment, Development, Death, Pancreatic cancer, Patient, Therapy, Cancer, Neoplasm, DNA, Pancreas, Standard of care, Survival, AMP, Poster, University, Lymphocyte, Risk, HLA, Safety, UCLA, Lymph, CA19-9, Immunization, University of California, PDAC, Research and development, Observation, Biopsy, Colorectal cancer, Nature Medicine, RAS, Pharmaceutical industry

The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).

Key Points: 
  • The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).
  • “We are progressing our AMP-powered, lymph node-targeted cancer vaccine, ELI-002 7P, as a monotherapy in an adjuvant setting for patients with pancreatic cancer, and recently dosed the first patient in the randomized Phase 2 cohort.
  • AMPLIFY-7P is a Phase 1 and Phase 2 study of ELI-002 7P in patients with RAS mutated pancreatic and colorectal tumors after locoregional treatment.
  • A Phase 2 interim analysis is planned using group sequential design for control of overall alpha 0.10.

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Retrieved on: 
Tuesday, November 28, 2023
Associate, Metastasis, Therapeutic endoscopy, Partnership, Neoplasm, Division, Death, Alpha Sigma Tau, Lung, Research, Breast, Radiation, General Hospital, Data, Pancreas, Alpha, Brain, Vulva, JGH, Endoscopy, Clinical trial, News, FRCPC, Pancreatic cancer, CA19-9, Radiation therapy, Interim, Assistant, McGill University, Translational research, Medical school, Patient, Safety, Neck

JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the release of interim results from treatment of the first five patients in the Company’s safety and feasibility trial examining the use of Alpha DaRT to treat advanced pancreatic cancer, currently underway at two university hospitals in Montreal, Canada.

Key Points: 
  • Tumor stages of the treated patients ranged from stage II to stage IV, and treated tumors were located in the pancreatic head or neck.
  • With respect to primary outcome measures, the Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumor.
  • The first two patients, who had received the fewest number of Alpha DaRT sources, both died approximately three months after treatment, and the deaths were not related to Alpha DaRT treatment.
  • The study primarily examines the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events.

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 9, 2023
Science, Research, Solar eclipse of August 21, 2017, Therapy, Injection, Doctor of Philosophy, HGG, CD8, SITC, Disease, Risk, Annual general meeting, Cancer, Insurance, Break, Society for Immunotherapy of Cancer, MOS, CADL, Prostate cancer, Immune system, Antibody, Breast cancer, Pancreatic cancer, Biomarker, Safety, Patient, Administration, Cohort, Survivor, MD, Rated R, CA19-9, Development, Immunotherapy, Clinical trial, SOC, Arm, Society, Content discovery platform, Survival, Progression-free survival, HSV, HSV-1, Valaciclovir, Herpes simplex, Quarter, B cell, Vaccine, Pharmaceutical industry, NSCLC, Nature, Candel, PDAC, Fellow of the Academy of Medical Sciences

“We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.

Key Points: 
  • “We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.
  • Research and Development Expenses: Research and development expenses were $5.8 million for the third quarter of 2023 compared to $5.4 million for the third quarter of 2022.
  • Research and development expenses included non-cash stock compensation expense of $0.3 million for both the third quarter of 2023 and the third quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the third quarter of 2023 and the third quarter of 2022.

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Retrieved on: 
Friday, November 3, 2023
Survival, Standard of care, Society for Immunotherapy of Cancer, CADL, Injection, Doctor of Philosophy, CA19-9, Poster, CD8, Pancreatitis, SITC, B cell, Cancer, Chemoradiotherapy, Recurrence, Annual general meeting, Pancreatic cancer, SOC, Tumor microenvironment, Therapy, Patient, Toxicity, MS, Vaccine, Pharmaceutical industry, Candel, MD, Fellow of the Academy of Medical Sciences, Immunotherapy, PDAC

Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.

Key Points: 
  • Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.
  • “Given frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective new treatment options are urgently needed,” said Garrett Nichols, MD, MS, Chief Medical Officer of Candel.
  • “We are encouraged by the improved survival associated with CAN-2409 for the treatment of borderline resectable PDAC, demonstrated for the first time in a randomized clinical trial.
  • Only one patient randomized to control SoC chemotherapy remained alive at data cut-off (alive at 43 months).

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Retrieved on: 
Monday, October 23, 2023
Survival, Patient, RT, ESMO, NBTXR3, MOS, Lymph, Head, PFS, MD, Monroe Dunaway Anderson, Doctor of Philosophy, Duration, CA19-9, Quality of life, NANO, Rated R, Chemoradiotherapy, Clinical trial, Pancreatic cancer, Oncology, University, Nanobiotix, Safety, European Society for Medical Oncology, Cancer, Progression-free survival, MD Anderson Cancer Center, OS, Diagnosis, Medical imaging, Residential care, Pharmaceutical industry, Euronext, LAPC

PARIS and CAMBRIDGE, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced updated data from two presentations at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO).

Key Points: 
  • The 5-year overall survival rate for patients with unresectable locally advanced pancreatic cancer (LAPC) remains less than 5%.
  • Normally, these patients receive the combination of cytotoxic chemotherapy followed by concurrent chemoradiation if no metastatic progression has occurred.
  • Innovative new treatments that might extend survival and avoid additional harmful side effects are an urgent unmet need for this patient population.
  • “With the Phase 1 study now complete, our focus is to ensure that we learn everything we can to anticipate the potential results of NANORAY-312.

Immunovia Publishes Interim Report for January-June 2023

Retrieved on: 
Wednesday, August 30, 2023
Pancreatic cancer, Partnership, Prevalence, Marketing, Annual, Research, Burn, Biomarker, SEK, ELISA, Cancer, Committee, Protein, Patient, Rights issue, Blood, CA19-9, Depreciation, Health, Bookkeeping, Cryptocurrency, Mobile phone, Pharmaceutical industry

On May 26, the Company published the summary of the resolutions made at the Annual General Meeting 2023.

Key Points: 
  • On May 26, the Company published the summary of the resolutions made at the Annual General Meeting 2023.
  • On June 9, the Company informed that Jeff Borcherding, CEO of Immunovia, purchased 350 000 shares for approximately kSEK 670.
  • As announced in July, we are significantly restructuring Immunovia to focus on our novel next-generation test for detection of pancreatic cancer.
  • Please know that we are working hard to create the company that will reward you for your investment in Immunovia.

Immunovia Publishes Interim Report for January-June 2023

Retrieved on: 
Wednesday, August 30, 2023
Pancreatic cancer, Partnership, Prevalence, Marketing, Annual, Research, Burn, Biomarker, SEK, ELISA, Cancer, Committee, Protein, Patient, Rights issue, Blood, CA19-9, Depreciation, Health, Bookkeeping, Cryptocurrency, Mobile phone, Pharmaceutical industry

On May 26, the Company published the summary of the resolutions made at the Annual General Meeting 2023.

Key Points: 
  • On May 26, the Company published the summary of the resolutions made at the Annual General Meeting 2023.
  • On June 9, the Company informed that Jeff Borcherding, CEO of Immunovia, purchased 350 000 shares for approximately kSEK 670.
  • As announced in July, we are significantly restructuring Immunovia to focus on our novel next-generation test for detection of pancreatic cancer.
  • Please know that we are working hard to create the company that will reward you for your investment in Immunovia.